These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 17425438)
1. Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic Swine model in vivo. El-Khatib FH; Jiang J; Gerrity RG; Damiano ER Diabetes Technol Ther; 2007 Apr; 9(2):135-44. PubMed ID: 17425438 [TBL] [Abstract][Full Text] [Related]
2. A feasibility study of bihormonal closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon in ambulatory diabetic swine. El-Khatib FH; Jiang J; Damiano ER J Diabetes Sci Technol; 2009 Jul; 3(4):789-803. PubMed ID: 20144330 [TBL] [Abstract][Full Text] [Related]
3. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment. Wan CK; Giacca A; Matsuhisa M; El-Bahrani B; Lam L; Rodgers C; Shi ZQ Metabolism; 2000 Aug; 49(8):984-9. PubMed ID: 10954014 [TBL] [Abstract][Full Text] [Related]
4. Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats. Pedersen C; Porsgaard T; Thomsen M; Rosenkilde MM; Roed NK PLoS One; 2018; 13(3):e0194468. PubMed ID: 29558502 [TBL] [Abstract][Full Text] [Related]
5. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Steil GM; Rebrin K; Darwin C; Hariri F; Saad MF Diabetes; 2006 Dec; 55(12):3344-50. PubMed ID: 17130478 [TBL] [Abstract][Full Text] [Related]
6. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats. Akarte AS; Srinivasan BP; Gandhi S Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634 [TBL] [Abstract][Full Text] [Related]
7. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878 [TBL] [Abstract][Full Text] [Related]
8. Increasing glucagon secretion could antagonize the action of exogenous insulin for glycemic control in streptozocin-induced diabetic rhesus monkeys. He S; Wang D; Lu Y; Chen Y; Jin X; Wang C; Zhao J; Ren Y; Wang L; Li H; Cheng J Exp Biol Med (Maywood); 2013 Apr; 238(4):385-91. PubMed ID: 23760004 [TBL] [Abstract][Full Text] [Related]
9. Dual self-regulated delivery of insulin and glucagon by a hybrid patch. Wang Z; Wang J; Li H; Yu J; Chen G; Kahkoska AR; Wu V; Zeng Y; Wen D; Miedema JR; Buse JB; Gu Z Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29512-29517. PubMed ID: 33177238 [TBL] [Abstract][Full Text] [Related]
10. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice. O'Harte FP; Franklin ZJ; Irwin N Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150 [TBL] [Abstract][Full Text] [Related]
11. A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. Bakhtiani PA; Caputo N; Castle JR; El Youssef J; Carroll JM; David LL; Roberts CT; Ward WK J Diabetes Sci Technol; 2015 Jan; 9(1):17-23. PubMed ID: 25253164 [TBL] [Abstract][Full Text] [Related]
12. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic Swine. El-Khatib FH; Jiang J; Damiano ER J Diabetes Sci Technol; 2007 Mar; 1(2):181-92. PubMed ID: 19888405 [TBL] [Abstract][Full Text] [Related]
13. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients. Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844 [TBL] [Abstract][Full Text] [Related]
15. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats. Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763 [TBL] [Abstract][Full Text] [Related]
16. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370 [TBL] [Abstract][Full Text] [Related]
17. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795 [TBL] [Abstract][Full Text] [Related]
18. Pharmacology of intravenous insulin administration: implications for future closed-loop glycemic control by the intravenous/intravenous route. Skjaervold NK; Lyng O; Spigset O; Aadahl P Diabetes Technol Ther; 2012 Jan; 14(1):23-9. PubMed ID: 21751892 [TBL] [Abstract][Full Text] [Related]
19. Effects of glucagon, glucose, adrenaline and insulin infusion on blood glucose level in the common African toad (bufo regularis). Oyebola DD; Ariwodola JO; Alada AR Afr J Med Med Sci; 1998; 27(1-2):89-94. PubMed ID: 10456139 [TBL] [Abstract][Full Text] [Related]
20. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Green BD; Gault VA; O'Harte FP; Flatt PR Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]